Nanaimo, BC-based
Tilray Inc. (
NASDAQ: TLRY) have published preliminary results finding that one of the company’s GMP-produced products is showing promise reducing nausea and vomiting for cancer patients undergoing chemotherapy in a world’s first clinical trial.
The Company says Australian researchers using some of its medical cannabis for a study on the drug’s ability to offset some effects of chemotherapy has shown "promise."
The preliminary results of the trial show that one-quarter of the cancer patients taking medicinal cannabis experienced no vomiting and nausea, compared to 14% of people who took a placebo. A total of 81 patients participated in the study, which took place over a two-and-a-half year period. The next stage of the trial has started, and it will look to recruit an additional 170 participants, one of the researchers said.
“Nausea and vomiting are among the most distressing and feared consequences of chemotherapy,” said chief investigator, Peter Grimison, medical oncologist at Chris O’Brien Lifehouse and Associate Professor at the University of Sydney. “These encouraging results indicate medicinal cannabis can help improve quality of life for chemotherapy patients.”
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub on Stockhouse.